Biomarkers /
MLLT1
Overview
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog; Drosophila); translocated to, 1 (MLLT1; also known as ENL) is a gene that encodes a protein that functions as a component of the super elongation complex (SEC). This complex facilitates the increase in the catalytic rate of RNA polymerase II. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as eye cancer, intestinal cancer, and skin cancer.
MLLT1 is altered in 0.12% of all cancers with lung adenocarcinoma, acute myeloid leukemia, bladder urothelial carcinoma, breast invasive ductal carcinoma, and cervical squamous cell carcinoma having the greatest prevalence of alterations [3].
The most common alterations in MLLT1 are MLLT1 Fusion (0.02%), MLLT1 T129M (0.28%), MLLT1 A290T (0.39%), MLLT1 E416K (0.85%), and MLLT1 N430T (0.39%) [3].
Clinical Trials
Significance of MLLT1 in Diseases
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.